4月21日，博济医药今日收盘9.15元，上涨2.58%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到78.60倍，总市值35.05亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均46.70倍，行业中值48.76倍，博济医药排 名第34位。 股东方面，截至2024年9月30日，博济医药股东户数22995户，较上次减少4424户，户均持股市值35.28 万元，户均持股数量2.76万股。 博济医药科技股份有限公司主要业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与 生产提供全流程"一站式"CRO服务。公司主要服务包括临床研究服务、临床前研究服务、CDMO服务、 其他咨询服务、临床前自主研发、技术成果转化服务等。作为国内领先的CRO公司，公司在报告期内 荣膺"2024中国医药CRO企业20强（排名第8）""2023年度中国医药研发50强""持续15年高新技术企 业"卓越成就奖等荣誉称号。 最新一期业绩显示，2024年三季报，公司实现营业收入5.56亿元，同比55.01%；净利润4327.78万元， 同比87.98%，销售毛利率32.19%。 序号股票简称PE(TTM)PE( ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Boji Pharmaceutical, which has a current stock price of 9.1 yuan and a rolling PE ratio of 78.17 times, significantly higher than the industry average of 46.29 times [1][2] - Boji Pharmaceutical's total market capitalization is 3.486 billion yuan, ranking 35th in the medical services industry based on PE ratio [1][2] - As of the third quarter of 2024, 51 institutions hold shares in Boji Pharmaceutical, with a total of 2.6617 million shares valued at 0.023 billion yuan [1] Group 2 - The company specializes in providing comprehensive CRO services for pharmaceutical companies and research institutions, including clinical research, preclinical research, CDMO services, and technology transfer [1] - Boji Pharmaceutical has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized as one of the top 50 pharmaceutical R&D companies in 2023 [1] - The latest financial results for the third quarter of 2024 show that the company achieved a revenue of 0.556 billion yuan, representing a year-on-year increase of 55.01%, and a net profit of 43.2778 million yuan, up 87.98% year-on-year, with a gross profit margin of 32.19% [1]